Evernorth, the health services division of Cigna, is debuting a pharmacy benefit management program geared to make Wegovy and Zepbound more available to patients by capping the amount they spend monthly on GLP-1 medications.
Through negotiations with the medications’ manufacturers, Everborth said it will cap patient’s monthly cost at no more than $200.
The goal, said Evernorth, is to fill a market need by offering savings and predictability.
